Calithera Biosciences, Inc. (NASDAQ:CALA) posted its earnings results on Thursday. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06, Bloomberg Earnings reports. The company had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million.

Shares of Calithera Biosciences (NASDAQ CALA) traded up $1.20 during trading hours on Friday, reaching $17.20. 871,398 shares of the company’s stock were exchanged, compared to its average volume of 446,269.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 16.30% of the stock is owned by corporate insiders.

A number of research firms have commented on CALA. BidaskClub cut shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. William Blair initiated coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Buy” and a consensus price target of $15.50.

ILLEGAL ACTIVITY WARNING: “Calithera Biosciences, Inc. (CALA) Announces Earnings Results” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Earnings History for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with's FREE daily email newsletter.